Sanofi plans four-fold increase in insulin production in Russia

French pharma major Sanofi (Euronext: SAN) plans to increase the volume of insulin production at its Russian plant operated by CJSC Sanofi-Aventis Vostok more than four-fold from the current 30 million to 136 million units and to diversify its product range, according to the company, reports The Pharma Letter’s local correspondent.

Implementation of these plans will take place in accordance with a special investment contract, which was recently signed by the company with the Russian government, which is designated for 10 years.

The contract involves increasing the local production of innovative insulin of the last generation to the stage of the finished dosage form, which should be completed by 2019. According to data of the Russian Ministry of Health, Sanofi currently produces 24% of the total volume of insulin available in Russia.